Skip to main content
. Author manuscript; available in PMC: 2010 Aug 1.
Published in final edited form as: Nutr Cancer. 2010 Aug;62(6):811–824. doi: 10.1080/01635581003693082

Fig. 4. Combinations of CUR and CA or SIL do not reduce the viability of normal human cells and differentially affect proliferation of phytohemagglutinin-stimulated human PBMC.

Fig. 4

A: Time-dependent changes in the viability of PBMC (peripheral blood mononuclear cells) and HSF (human skin fibroblasts) vs. HL-60 cells. Cells were incubated for 24-72 h with the indicated combinations of CUR and CA or CUR and SIL followed by the trypan blue exclusion assay. Reported values are the means ± SE (n=3). *, P = 0.047; §, P = 0.016; #, P < 0.0001. B: PBMC were incubated in 96-well plates (105 cells/well) with the indicated agents in the presence or absence 35 μg/ml PHA, for 72 h. Cell viability (upper panel) and proliferation (lower panel) were then determined by the trypan blue exclusion assay and 3H-thymidine incorporation assay, respectively, as described in the Materials and Methods. Reported values are the means ± SD of two independent experiments performed in sextuplicate. **, P < 0.01 and ***, P < 0.001, significant differences as compared to PHA-treated control cells; ‡, P < 0.01, significant difference between samples treated with 60 μM SIL alone and its combination with 5 μM CUR.